Holen Sie sich die Stockscreener-App
0.6463
3.77%
-0.0253
Vorhandelsmarkt:
.64
-0.0063
-0.97%
Schlusskurs vom Vortag:
$0.6716
Offen:
$0.6779
24-Stunden-Volumen:
2.01M
Relative Volume:
0.61
Marktkapitalisierung:
$253.72M
Einnahmen:
$86.26M
Nettoeinkommen (Verlust:
$-50.08M
KGV:
-2.639
EPS:
-0.2449
Netto-Cashflow:
$-94.48M
1W Leistung:
-13.80%
1M Leistung:
-23.96%
6M Leistung:
-42.81%
1J Leistung:
-47.46%
1-Tages-Spanne:
$0.6336
$0.6998
1-Wochen-Bereich:
$0.6336
$0.76
52-Wochen-Spanne:
$0.6336
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Firmenname
Standard Biotools Inc
Sektor
Branche
Telefon
(650) 266-6000
Adresse
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.6463 | 263.66M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-27 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | Eingeleitet | TD Cowen | Buy |
| 2024-04-04 | Eingeleitet | Jefferies | Buy |
| 2023-07-12 | Eingeleitet | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Aktie (LAB) Neueste Nachrichten
Long Focus Capital Management, LLC Adds to Standard BioTools Inc - GuruFocus
Standard BioTools (LAB) Slides 4.99% to $0.71 as Selling Pressure PersistsFactor Valuation - Vinanet
Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing - Stock Titan
Standard BioTools Inc.: Target Price Consensus and Analysts Recommendations | LAB | US34385P1084 - marketscreener.com
Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake - Stock Titan
Standard BioTools (LAB) Short Interest & Short Float | Updated Aug 2026 $LAB - MarketBeat
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Stock News Today - TradingKey
Is Standard BioTools Inc (LAB) Overvalued After Q2 Loss? EPS: -$0.21, Revenue: $20.1M -- GF Score: 33/100 - GuruFocus
Standard BioTools Inc. (LAB) Stock Report: Evaluating a Potential 93% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Standard BioTools (LAB) Holds Steady at $0.80: Consolidation or Pivot Point Ahead?Growth Stock Picks - dars.gov.et
BlackRock, Inc. Reduces Standard BioTools Inc (LAB) Stake -- Sha - GuruFocus
Standard BioTools Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Standard BioTools (NASDAQ:LAB) Issues Earnings Results - MarketBeat
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss - TradingKey
Standard BioTools Q2 revenue falls on consumables weakness - TradingView
STANDARD BIOTOOLS ($LAB) Releases Q2 2026 Earnings - Quiver Quantitative
STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary - TradingView
Standard BioTools: Q2 Earnings Snapshot - barchart.com
Standard BioTools (NASDAQ: LAB) Q2 revenue $20.1M as merger advances - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Standard BioTools Reports Second Quarter 2026 Financial Results - The Manila Times
BRIEF-Standard BioTools Q2 EPS USD -0.07 - TradingView
Standard Biotools Inc. Withdraws Earnings Guidance for the Full Year 2026 - marketscreener.com
Price to sales forward of Standard BioTools Inc. – BX:FLB - TradingView
Standard BioTools (LAB) CEO has 362,625 shares withheld for taxes - stocktitan.net
Standard BioTools Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Standard BioTools Inc. expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Standard BioTools Inc. (NASDAQ:LAB) Short Interest Update - MarketBeat
BlackRock (LAB) reports 7.9M-share, 2.0% position in Standard BioTools - Stock Titan
Standard BioTools Updates Disclosure on Mass Cytometry Business Sale to Multiplex Bio Amid Strategic Portfolio Restructuring - Kalkine Media
Form 4 Standard Biotools Inc For: 28 July By Investing.com - Investing.com Nigeria
Standard BioTools sells mass cytometry unit, gets $30M buyout By Investing.com - Investing.com Nigeria
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences - Moomoo
- SEC.gov
Standard BioTools (LAB) plans sale of Mass Cytometry business alongside Treeline deal - Stock Titan
Standard BioTools sells mass cytometry unit, gets $30M buyout - Investing.com
Standard BioTools Sells Mass Cytometry Business and Secures $30 Million Illumina Buyout Ahead of Treeline Merger - citybiz
Standard BioTools (NASDAQ: LAB) nets $30M Illumina buyout, sells mass cytometry arm - Stock Titan
Standard BiotoolsEnters Termination, Waiver And Release Agreement With Illumina On July 24, 2026SEC Filing - TradingView
Standard BioTools Sells Mass Cytometry Unit for $5 Million Note and Nets $30 Million From Illumina - TradingView
Standard BioTools Announces Sale of Mass Cytometry Business - GlobeNewswire
Standard BioTools Inc (LAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Standard BioTools Inc. Revenue Breakdown – NASDAQ:LAB - TradingView
Standard BioTools Ends Illumina Partnership, Sells Mass Cytometry Unit to Multiplex Bio for $5M - Kalkine Media
Form 4 Standard Biotools Inc For: 27 July By Investing.com - Investing.com Nigeria
Standard BioTools Inc. (LAB) CFO share withholding for tax obligations - Stock Titan
Standard BioTools Inc. Revenue Breakdown – GETTEX:FLB - TradingView
Standard BioTools Inc (LAB) Income Statement - TradingKey
Multiplex BioTech Private Limited agreed to acquire Mass Cytometry Business of Standard BioTools Inc. (NasdaqGS : LAB) for $10 million. - marketscreener.com
LAB|Standard BioTools Inc|Price:0.833|Chg%:-0.042 - TradingKey
Finanzdaten der Standard Biotools Inc-Aktie (LAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):